Aspirin and serum estrogens in postmenopausal women: A randomized controlled clinical trial

Cancer Prevention Research

Volumn 7, Issue 9, 2014, Pages 906-912

  Duggan, Catherine ^a   Wang, Ching Yun ^a   Xiao, Liren ^a   McTiernan, Anne ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTRADIOL; ESTROGEN; ESTRONE; PLACEBO; SEX HORMONE BINDING GLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY MASS; BREAST CANCER; BREAST DENSITY; CANCER RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; POPULATION RESEARCH; POSTMENOPAUSE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; THROMBOCYTE; TREATMENT DURATION; BLOOD; BREAST NEOPLASMS; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 84907288514     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0109     Document Type: Article

References (33)

1. Abou-Issa H, Alshafie G, Harris R. Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. COX-2 blockade in cancer prevention and therapy. Totowa, NJ: Humana Press; 2002. p. 95-8.
2. Alshafie G, Harris R, Robertson F, Parrett M, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Res 1999;19:3031-6.
3. Joarder F, Abou-Issa H, Robertson F, Parrett M, Alshafie G, Harris R. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in Sprague-Dawley rats. Oncol Rep 1997;4:1271-3.
4. Lee I-M, Sesso HD, Paffenbarger RS. Physical activity and risk of lung cancer. Int J Epidemiol 1999;28:620-5.
5. Steele V, Moon R, Lubet R. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994;20:32-54.
6. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-47.
7. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012;30:3468-77.
8. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Int Med 2013;159:77-85.
9. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Nat Cancer Inst 1998;90:1529-36.
10. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
11. Brueggemeier R, Quinn A, Parrett M, Joarder F, Harris R, Robertson F. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35.
12. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, et al. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:680-7.
13. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
14. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metabol 2005;90:2563-70.
15. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:1033-41.
16. Harris R, Namboodiri K, Farrar W. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
17. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013;19:6074-83.
18. Baron J, Cole B, Sandler R, Haile R, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 2003;348:891-9.
19. Sandler R, Halabi S, Baron J, Budinger S, Paskett E, Keresztes R, et al. Arandomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med 2003;348:883-90.
20. [Erratum in N Engl J Med. 2003 May 8:348,1939]
21. McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DS, Aiello Bowles EJ, et al. No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2009; 18:1524-30.
22. American College of Radiology. Breast Imaging-Reporting and Data System (BI-RADS). 3rd ed. Reston, VA: American College of Radiology; 1998.
23. Goebelsmann U, Bernstein GS, Gale JA, Kletzky OA, Nakmura RM, Coulson AH, et al. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: Lepow IH, Crozier R, editors. Vasectomy: immunologic and pathophysiologic effect in animals and man. New York: Academic Press; 1979. p. 165.
24. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-73.
25. Sodergard R, BackstromT, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metabol 1999;84:3666-72.
27. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002; 11:1065-71.
28. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization technical report series; 1995. Report No.: 854:1-452.
29. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 2006;14:1662-77.
30. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol 2012;30:2314-26.
31. Harris R, Chlebowski R, Jackson R, Frid D, Ascenseo J, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
32. Terry M, Gammon M, Zhang F, Tawfik H, Teitelbaum S, Britton J, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291:2433-40.
33. Hudis CA, Subbaramaiah K, Morris PG, Dannenberg AJ. Breast cancer risk reduction: no pain, no gain? J Clin Oncol 2012;30:3436-8.